Abstract：Objective: To explore the diagnostic value of combined detection of serum human epididymis protein 4 (HE4), cytoplasmic thymidine kinase (TK1) and carbohydrate antigen 199 (CA199) for ovarian cancer. Methods: 124 cases of patients with pelvic tumors who were undergoing surgical treatment in our hospital from March 2016 to March 2018 were selected for the study. According to the results of postoperative pathological examination, the patients were divided into ovarian cancer group (n=64) and benign ovarian disease group (n=60). And another 66 healthy women who were for physical examination at the same time were randomly selected as control group. The levels of serum HE4, TK1 and CA199 were compared among the three groups. The receiver operating characteristic curve was used to evaluate the diagnostic value [sensitivity, specificity, and area under curve (AUC)] of single index detection and combined detection of the three indexes. Results: The levels of serum HE4, TK1 and CA199 and positive rate of each single index in ovarian cancer group were higher than those in benign ovarian disease group and control group (P<0.05), and the levels of serum HE4, TK1 and CA199 and positive rate of each single index in benign ovarian disease group were higher than those in control group (P<0.05). The sensitivity and AUC of combined detection of the three indexes for ovarian cancer were higher than those of single index detection (P<0.05), and there was no significant difference in the specificity compared with that of single index detection (P>0.05). Conclusions: The expression levels of serum HE4, TK1 and CA199 are different in patients with ovarian cancer, patients with benign ovarian disease and healthy people. They can be used as sensitive indicators for ovarian cancer diagnosis, and combined detection of the three indexes can improve the diagnostic accuracy.
王春阳, 王羽, 王子龙. 血清HE4 TK1 CA199联合检测对卵巢癌的诊断价值[J]. 河北医学, 2019, 25(7): 1081-1084.
WANG Chunyang, WANG Yu, et al. Diagnostic Value of Combined Detection of Serum HE4 TK1 and CA199 for Ovarian Cancer. HeBei Med, 2019, 25(7): 1081-1084.
2019, Vol. 25 
冀公网安备13080202000677号